secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2024-01-22T23:59:59+00:00
Accession:  0001104659-24-005579
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cara ends CKD program, cuts 50% staff, focuses on NP; cash into 2026
--------------------------------------------------------------------

- Terminated Phase 3 oral difelikefalin program in pruritus with advanced CKD; KICK 1/2 trials stopped.
- Workforce reduced by up to 50%; expects $2.5M-$3M Q1 2024 charges for termination benefits.
- Cash ~$101M at year-end 2023; runway extended into 2026, funding NP program to milestones.
- Phase 2/3 KOURAGE trial in notalgia paresthetica dose-finding readout expected Q3 2024, pivotal data by 2025/2026.
- CSO Frédérique Menzaghi, Ph.D., to depart effective Feb 2, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465924005579/0001104659-24-005579-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465924005579/tm243779d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-005579

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer